Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 5, 2005, Pages 620-625

  Lau, Bryan ^a   Gange, Stephen J ^a   Phair, John P ^b   Riddler, Sharon A ^c   Detels, Roger ^d   Margolick, Joseph B ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alternative markers; Cohort study; Markers of disease progression; Natural history

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HEMOGLOBIN; VIRUS RNA;

ACCURACY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DISEASE COURSE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; T LYMPHOCYTE SUBPOPULATION; WORLD HEALTH ORGANIZATION;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HEMOGLOBINS; HIV INFECTIONS; HUMANS; LYMPHOCYTE COUNT; MALE; PROPORTIONAL HAZARDS MODELS;

EID: 23244432933     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. UNAIDS Joint United Nations Programme on HIV/AIDS. Report on the global HIV/AIDS epidemic 2004. June 2004. Available at: http://www. unaids.org/bangkok2004/report.html. Accessed February 15, 2005.
2. Weidle PJ, Mastro TD, Grant AD, et al. HIV/AIDS treatment and HIV vaccines for Africa. Lancet. 2002;359:2261-2267.
3. Centers for Disease Control and Prevention. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Morb Mortal Wkly Rep. 2002;51(RR-7):1-55.
4. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings. Guidelines for a public health approach. Available at: http://www.who.int/HIV_AIDS. Accessed July 1, 2002.
5. Rabkin M, El-Sadr W, Katzenstein DA, et al. Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet. 2002;360: 1503-1505.
6. Office of AIDS Research. Fiscal year 2004 NIH plan for HIV-related research. II: Natural history and epidemiology. Available at: http:// www.nih.gov/od/oar/public/public.htm. Accessed August 1, 2003.
7. Morcroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS. 1999;13:943-950.
8. Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:29-33.
9. Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the Multistate Adult and Adolescent Spectrum of HIV Disease Surveillance Project. Blood. 1998;1:302-308.
10. Anastos K, Shi Q, French AL, et al. Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2004;35:383-392.
11. Beck EJ, Kupek EJ, Compels MM, et al. Correlation between total and CD4 lymphocyte counts in HIV infection: not making the good an enemy of the not so perfect. Int J STD AIDS. 1996;7:422-428.
12. Post FA, Wood R, Maartens G. CD4 and total lymphocyte counts as predictors of HIV disease progression. Q J Med. 1996;89:505-508.
13. + percentage in a group of HIV-1 infected South African patients. J Acquir Immune Defic Syndr. 1998;19:238-244.
14. Jacobson MA, Liu L, Kyahyam-Bashi H, et al. Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte: criterion for initiating antiretroviral therapy. AIDS. 2003;17:917-919.
15. Schreibman T, Friedland G. Use of total lymphocyte count for monitoring response to antiretroviral therapy. Clin Infect Dis. 2004;38:257-262.
16. Bardi M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. AIDS. 2003;17:541-545.
17. Mahajan AP, Hogan JW, Snyder B, et al. Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource-limited settings. J Acquir Immune Defic Syndr. 2004;36:567-575.
18. Lau B, Gange SJ, Phair JP, et al. Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-I infected men. AIDS. 2003;17:2035-2044.
19. Margolick JB, Munoz A, Donnenberg AD, et al. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort Study. Nat Med. 1995;1:674-680.
20. Gange SJ, Mellors JW, Lau B, et al. Longitudinal patterns of HIV type 1 RNA among individuals with late disease progression. AIDS Res Hum Retroviruses. 2001;17:1223-1229.
21. Gange SJ, Lau B, Phair J, et al. Rapid declines in total lymphocyte count and hemoglobin in HIV infection begin at CD4 lymphocyte counts that justify antiretroviral therapy. AIDS. 2003;17:119-131.
22. Kaslow RA, Ostrow DG, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126:310-318.
23. Giorgi JV, Cheng HL, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the Multicenter AIDS Cohort Study experience. The Multicenter AIDS Cohort Study Group. Clin Immunol Immunopathol. 1990;55:173-186.
24. Schenker EL, Hultin LE, Bauer KD, et al. Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. Cytometry. 1993;14:307-317.
25. Gange SJ, Muñoz A, Chmiel JS, et al. Identification of inflections in T-cell counts among HIV-1-infected individuals and relationship with progression to clinical AIDS. Proc Natl Acad Sci USA. 1998;95:10848-10853.
26. Maas JJ, Gange SJ, Schuitemaker H, et al. Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study. AIDS. 2000; 14:1155-1161.
27. Shankarappa R, Margolick JB, Gange SJ, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol. 1999;73:10489-10502.
28. Margolick JB, Donnenberg AD, Chu C, et al. Decline in total T cell count is associated with onset of AIDS, independent of CD4(+) count: implications for AIDS pathogenesis. Clin Immunol Immunopathol. 1998; 88:256-263.
29. Bahner I, Kerans K, Coutinho S, et al. Infection of human marrow stroma by HIV-1 is both required and sufficient for HIV-1 induced hematopoietic suppression in vitro: demonstration by gene modification of primary human stroma. Blood. 1997;90:1787-1798.
30. Scadden DT, Zeira M, Woon A, et al. Human immunodeficiency virus infection of human bone marrow stromal fibroblasts. Blood. 1990;76: 317-322.
31. Claster S. Biology of anemia, differential diagnosis and treatment options in human immunodeficiency virus infection. J Infect Dis. 2002;185 (Suppl 2):S105-S109.
32. Lyles RH, Muñoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis. 2000;181:872-880.
33. Feldman JG, Burns DN, Gange SJ, et al. Serum albumin as a predictor of survival in HIV-infected women in the Women's Interagency HIV Study. AIDS. 2000;14:863-870.
34. Sabin CA, Griffioen A, Yee TT, et al. Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal study. Lancet. 2002;360:1546-1551.
35. Feldman JG, Gange SJ, Bacchetti P, et al. Serum albumin is a powerful predictor of survival among HIV-1-infected women. J Acquir Immune Defic Syndr. 2003;33:66-73.